Choline PET (C-11 / F-18-Fluorocholine)¹¹C-choline · ¹⁸F-fluoromethylcholine
Membrane-synthesis PET for prostate cancer and hyperfunctioning parathyroid
Quick Answer
Choline PET tracers (C-11-choline, F-18-fluorocholine) exploit upregulated membrane phospholipid synthesis in proliferating cells: choline is taken up (choline transporters), phosphorylated by choline kinase, and incorporated into phosphatidylcholine of cell membranes. It was a workhorse for biochemically recurrent prostate cancer before PSMA-PET (which now largely supersedes it, with higher low-PSA detection), and F-18-fluorocholine has a strong second role in parathyroid adenoma localization, where it often outperforms sestamibi. Choline has low urinary excretion early, aiding pelvic/prostate-bed assessment.
Mechanism
Choline enters cells via choline transporters, is trapped by choline-kinase phosphorylation, and incorporated into membrane phosphatidylcholine — so uptake reflects membrane-synthesis/proliferation. Malignant and hyperfunctioning cells with high membrane turnover concentrate it. C-11 requires an on-site cyclotron (20-min half-life); F-18-fluorocholine allows distribution.
Biodistribution
Liver, kidneys, pancreas, spleen, salivary glands, and low early urinary excretion (advantage for the prostate bed; F-18 shows more delayed urinary activity than C-11).
Clinical Indications
- Biochemically recurrent prostate cancer — localizing disease (now largely second-line to PSMA-PET, used where PSMA is unavailable; detection rises with PSA).
- Parathyroid adenoma localization — F-18-fluorocholine PET/CT, higher sensitivity than sestamibi, especially for small, sestamibi-negative, or multiglandular disease.
- Occasional roles in hepatocellular carcinoma (complementary to FDG) and brain tumors.
Preparation & Protocol
- Standard PET/CT; early pelvic imaging for prostate (before urinary activity accumulates).
- Parathyroid: early (and sometimes dual-time) imaging; correlate with neck US/4D-CT.
- Record agent (C-11 vs F-18) and uptake time.
Interpretation Highlights
- Prostate recurrence: focal nodal/bed/osseous uptake; detection scales with PSA but is lower than PSMA-PET at matched PSA.
- Parathyroid: focal uptake exceeding thyroid marks the hyperfunctioning gland; concordant with US/4D-CT strengthens localization.
- Uptake is not tumor-specific — inflammation and benign proliferative tissue also take it up.
Reporting Checklist
- State the agent, uptake time, and clinical question (prostate vs parathyroid).
- For prostate, classify local/nodal/distant disease; note PSA context.
- For parathyroid, report localization and concordance with anatomic imaging.
Common Pitfalls
- Using choline where PSMA-PET (higher low-PSA detection) is available for prostate recurrence.
- Inflammatory/benign uptake causing false positives.
- C-11's 20-min half-life requiring an on-site cyclotron (logistics).
Board Pearls
Choline PET (C-11-choline / F-18-fluorocholine) images membrane phospholipid synthesis — choline is phosphorylated by choline kinase and incorporated into phosphatidylcholine. It was a workhorse for recurrent prostate cancer but is now largely second-line to PSMA-PET (higher low-PSA detection); its low early urinary excretion aids the prostate bed.
F-18-fluorocholine has a strong parathyroid role — localizing hyperfunctioning parathyroid adenomas with higher sensitivity than sestamibi, especially for small, sestamibi-negative, or multiglandular disease.
C-11 needs an on-site cyclotron (20-min half-life); F-18-fluorocholine allows distribution but shows more delayed urinary activity. Uptake reflects proliferation/membrane turnover and is not tumor-specific (inflammation, benign proliferative tissue). In prostate recurrence, detection scales with PSA but trails PSMA at matched PSA — the reason for the field's shift.
Related Pages
- Tracers: PSMA PET agents (successor), fluciclovine (amino-acid alternative); diseases: Prostate cancer, PSMA biochemical recurrence; related: Parathyroid imaging.
Figure / Diagram Suggestions
- A choline-kinase → phosphatidylcholine membrane-synthesis cartoon.
- A fluorocholine parathyroid vs sestamibi localization comparison.
Self-Check
Q1. What biologic process does choline PET image, and via what key enzyme?
Answer: Membrane phospholipid synthesis/proliferation — choline is trapped by choline kinase phosphorylation and incorporated into phosphatidylcholine.
Q2. Why has PSMA-PET largely replaced choline for prostate recurrence?
Answer: PSMA-PET has higher detection, especially at low PSA; choline is now used mainly where PSMA is unavailable.
Q3. What is the strong second clinical role of F-18-fluorocholine?
Answer: Parathyroid adenoma localization — often outperforming sestamibi, especially for small/sestamibi-negative/multiglandular disease.
Q4. What logistical limitation does C-11-choline have that F-18-fluorocholine does not?
Answer: C-11's 20-minute half-life requires an on-site cyclotron; F-18 allows distribution.
Evidence & sources
https://nuc.med/choline-pet/ Report an issue